J&J does Alzheimer's gene ther­a­py deal, along with 14 oth­er new col­lab­o­ra­tions

John­son & John­son has inked a re­search deal with Uni­ver­si­ty of Penn­syl­va­nia to work on gene ther­a­py for Alzheimer’s. The part­ner­ship lever­ages the uni­ver­si­ty’s ade­no-as­so­ci­at­ed virus­es and J&J’s an­ti-Alzheimer’s an­ti­bod­ies in hopes to pen­e­trate the blood brain bar­ri­er.

The part­ner­ship in­volves the phar­ma gi­ant’s in­no­va­tion-fo­cused arm John­son & John­son In­no­va­tion and Janssen Phar­ma­ceu­ti­cals. J&J hopes to use the uni­ver­si­ty’s AAV vi­ral de­liv­ery to trig­ger the ex­pres­sion of ther­a­peu­tic an­ti­bod­ies to the brain – an ef­fort that would change the sta­tus quo. Cur­rent­ly, the blood brain bar­ri­er lim­its the use of an­ti­bod­ies to treat brain dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER